Gilead Sciences, Inc. to Present New Hepatitis B and C Data at European Conference on Liver Disease This Week

BARCELONA, Spain--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that 30 abstracts examining the company’s products and investigational agents for hepatitis B and C have been selected for presentation at the 47th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2012) taking place April 18-22 in Barcelona, Spain. The abstracts describe clinical and preclinical data for a number of investigational chronic hepatitis C compounds, as well as new long-term data for Viread® (tenofovir disoproxil fumarate) for chronic hepatitis B.

MORE ON THIS TOPIC